Huber Capital Management LLC Has $5.19 Million Position in Kenvue Inc. $KVUE

Key Points

• Huber Capital Management increased its Kenvue stake by 23.7% in the fourth quarter, buying 57,594 more shares and bringing its total holdings to 300,894 shares worth about $5.19 million.
• Kenvue reported better-than-expected quarterly results, posting EPS of $0.32 versus $0.27 expected and revenue of $3.91 billion versus $3.84 billion expected, with revenue up 4.5% year over year.
• The company paid a quarterly dividend of $0.2075, annualizing to $0.83 per share for a 4.6% yield, while analysts currently have a consensus Hold rating and an average price target of $19.33.

Huber Capital Management LLC boosted its position in Kenvue Inc. (NYSE:KVUE - Free Report) by 23.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 300,894 shares of the company's stock after purchasing an additional 57,594 shares during the period. Huber Capital Management LLC's holdings in Kenvue were worth $5,190,000 at the end of the most recent quarter.

A number of other institutional investors and hedge funds have also bought and sold shares of the company. Physician Wealth Advisors Inc. increased its holdings in Kenvue by 67.5% in the 4th quarter. Physician Wealth Advisors Inc. now owns 1,533 shares of the company's stock worth $26,000 after purchasing an additional 618 shares in the last quarter. B & T Capital Management DBA Alpha Capital Management increased its holdings in Kenvue by 0.3% in the 4th quarter. B & T Capital Management DBA Alpha Capital Management now owns 234,664 shares of the company's stock worth $4,048,000 after purchasing an additional 712 shares in the last quarter. Philip James Wealth Mangement LLC increased its holdings in Kenvue by 5.5% in the 4th quarter. Philip James Wealth Mangement LLC now owns 13,888 shares of the company's stock worth $240,000 after purchasing an additional 726 shares in the last quarter. IFG Advisory LLC increased its holdings in Kenvue by 5.4% in the 4th quarter. IFG Advisory LLC now owns 15,051 shares of the company's stock worth $260,000 after purchasing an additional 766 shares in the last quarter. Finally, Phoenix Financial Ltd. increased its holdings in Kenvue by 5.4% in the 4th quarter. Phoenix Financial Ltd. now owns 15,195 shares of the company's stock worth $262,000 after purchasing an additional 783 shares in the last quarter. Institutional investors and hedge funds own 97.64% of the company's stock.

Insider Activity at Kenvue

In related news, General Counsel Matthew Orlando sold 38,491 shares of Kenvue stock in a transaction that occurred on Friday, May 8th. The stock was sold at an average price of $17.66, for a total value of $679,751.06. The transaction was disclosed in a document filed with the SEC, which can be accessed through this link. 1.59% of the stock is currently owned by corporate insiders.

Kenvue Price Performance

Kenvue stock opened at $18.13 on Friday. The stock's 50 day moving average is $17.43 and its 200 day moving average is $17.53. The company has a debt-to-equity ratio of 0.67, a current ratio of 0.98 and a quick ratio of 0.70. The firm has a market cap of $34.80 billion, a P/E ratio of 21.32, a P/E/G ratio of 1.38 and a beta of 0.54. Kenvue Inc. has a one year low of $14.02 and a one year high of $22.87.

Kenvue (NYSE:KVUE - Get Free Report) last posted its quarterly earnings data on Thursday, May 7th. The company reported $0.32 EPS for the quarter, topping analysts' consensus estimates of $0.27 by $0.05. The company had revenue of $3.91 billion for the quarter, compared to analyst estimates of $3.84 billion. Kenvue had a return on equity of 20.81% and a net margin of 10.61%.The firm's quarterly revenue was up 4.5% on a year-over-year basis. During the same period in the previous year, the firm earned $0.24 earnings per share. As a group, research analysts expect that Kenvue Inc. will post 1.16 EPS for the current year.

Kenvue Dividend Announcement

The business also recently disclosed a quarterly dividend, which was paid on Wednesday, May 27th. Investors of record on Wednesday, May 13th were paid a $0.2075 dividend. This represents a $0.83 dividend on an annualized basis and a dividend yield of 4.6%. The ex-dividend date of this dividend was Wednesday, May 13th. Kenvue's payout ratio is currently 97.65%.

Analysts Set New Price Targets

A number of brokerages have issued reports on KVUE. Zacks Research raised Kenvue from a "hold" rating to a "strong-buy" rating in a report on Friday, May 8th. Weiss Ratings cut Kenvue from a "hold (c)" rating to a "hold (c-)" rating in a report on Friday, May 29th. Argus raised Kenvue to a "hold" rating in a report on Friday, March 6th. Canaccord Genuity Group upped their target price on Kenvue from $17.00 to $18.00 and gave the stock a "hold" rating in a report on Wednesday, February 18th. Finally, Citigroup lowered their target price on Kenvue from $20.00 to $19.00 and set a "neutral" rating for the company in a report on Wednesday, April 15th. One equities research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating and twelve have given a Hold rating to the stock. Based on data from MarketBeat.com, the company presently has a consensus rating of "Hold" and an average price target of $19.33.

Kenvue Company Profile

Kenvue is a consumer health company that was established as a standalone, publicly traded business after separating from Johnson & Johnson. Listed on the New York Stock Exchange under the symbol KVUE, Kenvue focuses on the development, manufacture, marketing and distribution of consumer health and personal care products across a range of categories including skin and beauty care, baby care, oral care, wound care and over‑the‑counter medicines.

The company owns and markets a portfolio of widely recognized consumer brands, including names familiar to global shoppers across retail and pharmacy channels.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.